What is GH's health score?

Guardant Health, Inc. (GH) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is GH's estimated fair value?

Based on our 5-year discounted cash flow model, Guardant Health, Inc.'s estimated fair value is $10.61 per share, representing a -91.6% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is GH undervalued or overvalued?

Our model currently rates GH as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for GH... Refresh in a moment for the full analysis.

Guardant Health, Inc. (GH)

Healthcare Overvalued low weak

$125.61

Updated: 2026-06-06

TradeApes Score

Financial Strength

40 Weak

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk

50 Mixed

Est. Fair Value $10.61

DCF Upside -91.6%

Sector Rank #520 of 6579

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.